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We have previously shown that intracellular trafficking and extracellular assembly of tropoelastin into elastic fibers
is facilitated by the 67-kD elastin-binding protein identical to an enzymatically inactive, alternatively spliced variant
of b-galactosidase (S-Gal). In the present study, we investigated elastic-fiber assembly in cultures of dermal fibroblasts
from patients with either Morquio B disease or GM1-gangliosidosis who bore different mutations of the b-galac-
tosidase gene. We found that fibroblasts taken from patients with an adult form of GM1-gangliosidosis and from
patients with an infantile form, carrying a missense mutations in the b-galactosidase gene—mutations that caused
deficiency in lysosomal b-galactosidase but not in S-Gal—assembled normal elastic fibers. In contrast, fibroblasts
from two cases of infantile GM1-gangliosidosis that bear nonsense mutations of the b-galactosidase gene, as well
as fibroblasts from four patients with Morquio B who had mutations causing deficiency in both forms of b-
galactosidase, did not assemble elastic fibers. We also demonstrated that S-Gal–deficient fibroblasts from patients
with either GM1-gangliosidosis or Morquio B can acquire the S-Gal protein, produced by coculturing of Chinese
hamster ovary cells permanently transected with S-Gal cDNA, resulting in improved deposition of elastic fibers.
The present study provides a novel and natural model validating functional roles of S-Gal in elastogenesis and
elucidates an association between impaired elastogenesis and the development of connective-tissue disorders in
patients with Morquio B disease and in patients with an infantile form of GM1-gangliosidosis.
Introduction
Deficiency in acid lysosomal b-galactosidase (b-Gal
[E.C.3.2.1.23]) activity is the primary defect in GM1-
gangliosidosis and Morquio disease type B, two clini-
cally different entities. So far, ∼30 mutations have been
identified in the b-Gal gene (for a review, see Callahan
1999). GM1-gangliosidosis is a progressive neurovis-
ceral disease in which three distinct phenotypic variants
are recognized—an infantile (MIM 230500), a juvenile
(MIM 230600), and an adult (MIM 230650)—on the
basis of both age at onset and severity of the symptoms
(Suzuki et al. 1995). All patients with GM1-gangliosi-
dosis store GM1-gangliosides in neurons (Mutoh et al.
1986, 1988), but only patients with the infantile form
of this disease display coarse facial features, hepato-
splenomegaly, prominent skeletal dysmorphology (Alroy
et al. 1992, 1995; Suzuki et al. 1995), diverse connective-
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tissue abnormalities, and cardiomyopathy. The latter
feature is an atypical clinical manifestation that has been
reported only in White patients (Hadley and Hagstrom
1971; Benson et al. 1976; Kohlschutter et al. 1982; Ro-
senberg et al. 1985; Charrow and Hvizd 1986; Morrone
et al. 2000). In contrast, patients withMorquio B disease
(MIM 253010) do not store GM1-gangliosides in the
brain and are neurologically normal but display more-
severe connective-tissue and skeletal deformities than are
seen in GM1-gangliosidosis (Arbisser et al. 1977;
Groebe et al. 1980; van der Horst et al. 1983; Giugliani
et al. 1987). They may also display cardiac-valve de-
formations, aortic stenosis, and intimal thickening in the
coronary arteries and in the pulmonary artery (Factor
et al. 1978; Haust 1987; Dangel 1998). Development of
the connective-tissue and skeletal abnormalities, both in
patients with GM1-gangliosidosis and in patients with
Morquio B, has been largely attributed to the intra- and
extracellular storage of galactose-terminal oligosaccha-
rides derived primarily from the breakdown of glyco-
proteins and complex glycosaminoglycans. Alternative
pathomechanisms that may contribute to abnormalities
of the extracellular matrix and development of char-
acteristic clinical phenotypes in these diseases have not
been recognized.
We have recently demonstrated that defective for-
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mation of elastic fibers in tissues of patients with Hurler
disease and in patients with Costello syndrome can be
directly linked to the development of connective-tissue
and cardiovascular disorders, as well as to skeletal de-
formations observed in these clinical entities, also char-
acterized by accumulation of galactose-containing moi-
eties (Hinek and Wilson 2000; Hinek et al. 2000).
The mature elastic fibers and laminae present in con-
nective tissues and blood vessel walls are complex struc-
tures made of polymeric (insoluble) elastin in which
polypeptide chains of tropoelastin are covalently cross-
linked and placed on a scaffold of 12-nm microfibrils
that consists of several glycoproteins—for example, fi-
brillins and microfibril-associated glycoproteins (Me-
cham and Hauser 1991; Rosenbloom et al. 1993; Chris-
tiano and Uitto 1994; Pasquali-Ronchetti and Bac-
carani-Contri 1997). Tropoelastin is a soluble 70-kD
precursor of extracellular elastin (for reviews, see
Vrhovski and Weiss 1998; Debell and Tamburro 1999)
synthesized by such cells as fibroblasts, chondrocytes,
and smooth-muscle cells, which have to be secreted and
properly positioned on the microfibrillar scaffold (Sakai
et al. 1986; Zhang et al. 1994; Kielty and Shuttleworth
1995; Gibson et al. 1996) before being cross-linked by
lysyl oxidase (Kagan et al. 1986).
Our group has shown elsewhere that early stages of
elastogenesis are controlled by the 67-kD elastin-bind-
ing protein (EBP), which also has a galactolectin domain
that can bind galactosugar-bearing moieties (Hinek et
al. 1988, 1991, 1993; Mecham et al. 1989, 1991; Pri-
vitera et al. 1998). The EBP acts as a recyclingmolecular
chaperone that protects the highly hydrophobic tro-
poelastin molecules from intracellular self-aggregation
and premature degradation (Hinek and Rabinovitch
1994; Hinek et al. 1995). The EBP also facilitates the
orderly assembly of tropoelastin upon the microfibrillar
scaffold of growing elastic fibers (Hinek 1994, 1996).
The orderly release of tropoelastin from its transpor-
tation complex with the EBP occurs at the cell surface,
just after the galactolectin domain of the EBP binds to
galactosugars residues, protruding from polyglycosylat-
ed fibrillin molecules and from fibrillin-associated chon-
droitin sulfate proteoglycans (Hinek et al. 1995; Hinek
1996; Kielty et al. 1996).
We have established that elastogenesis can be dis-
rupted by pericellular accumulation of galactosugar-
bearing moieties, such as chondroitin sulfate or der-
matan sulfate, which also can bind to the galactolectin
domain of EBP and can induce both its shedding from
the cell surface and premature release of tropoelastin,
far from microfibrillar acceptors (Hinek et al. 1988,
1991; Hinek and Rabinovitch 1994). Most important,
results of our previous studies (Hinek et al. 1993; Pri-
vitera et al. 1998) led to the discovery that the 67-kD
EBP is identical to the alternatively spliced, catalytically
inactive variant of human b-Gal (S-Gal), originally de-
scribed as a protein with undefined function (Morreau
et al. 1989; Yamamoto et al. 1990).
S-Gal arises through the splicing-out of two noncon-
tiguous encoding regions from the mRNA, in such a
way that the first deletion introduces a frameshift (exon
5), which is restored by the deletion of a second region.
The net result is synthesis of a shortened protein that
does not display any enzymatic activity of b-Gal and is
not targeted to the lysosomes. We have established that
a unique 32-amino-acid-long domain encoded by the
frameshifted exon 5 of S-Gal contains a VVGSPSAQ-
DEASPL sequence that binds elastin and laminin (Hinek
et al. 1993).
The in vitro transcription/translation of a full-length
cDNA clone encoding human S-Gal produced protein
that reacted with anti–b-Gal, anti–S-Gal and anti-EBP
antibodies and that bound to the elastin- and laminin-
affinity columns. S-Gal cDNA transfection of the EBP-
deficient smooth-muscle cells (SMC) taken from intimal
cushions of the ductus arteriosus also up-regulated their
expression of functional 67-kD EBP. In contrast to their
untransfected counterparts, the S-Gal–transfected duc-
tus arteriosus SMC attached to elastin-covered plates
and displayed normal assembly of elastic fibers in cul-
ture (Privitera et al. 1998).
In this study, we tested expression of S-Gal/EBP and
assessed elastic-fiber formation in cultures of skin fi-
broblasts obtained from four patients with Morquio
B disease that bear b-Gal gene mutations (G438E,
N484K/T500A, and W273L/R482H) localized to the
coding region common to lysosomal enzyme and S-Gal/
EBP protein. We also tested S-Gal/EBP expression and
elastogenesis in (a) fibroblasts from two patients with
GM1-gangliosidosis that bear a missense R148S mu-
tation localized to the exon 4 of the b-Gal gene that is
spliced out of S-Gal and that might not affect synthesis
of S-Gal protein and (b) fibroblasts from two patients
with GM1 that bear either one of two nonsense mu-
tations (R351X and R475X) that likely destabilize both
b-Gal and S-Gal mRNAs and that, consequently, lead
to deficiency in both protein variants. Our studies,
aimed at establishing the connection between the ex-
pression of S-Gal and elastogenesis, also included fi-
broblasts from two patients with an adult form of GM1-
gangliosidosis that did not display any connective-tissue
problems.
Material and Methods
Material
Chemicals and reagents were obtained as follows.Me-
dia, fetal bovine serum, and other tissue-culture reagents
were obtained from GIBCO. Polyclonal antibody to bo-
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vine tropoelastin (Prosser et al. 1991), polyclonal anti-
body to fibrillin 1, and BCZmonoclonal antibody raised
to bovine EBP (Mecham et al. 1988) were purchased
from Elastin Products Co., Inc. Monoclonal antibody to
fibronectin (mAB1940) was from Chemicon, and mono-
clonal anti-laminin antibody was obtained from ICN.
Polyclonal antibodies to human collagen type I and to
human lysyl oxidase were generous gifts fromDrs. Larry
W. Fischer (National Institutes of Health) and Katalin
Csiszar (University of Hawaii at Manoa), respectively.
The polyclonal antibodies anti–S-Gal, raised to VV-
GSPSAQDEASPL oligopeptide, corresponding to the
elastin-binding domain of the alternatively spliced form
of human b-Gal; anti–C-Gal, raised to PPQKNKD-
SWLDHV oligopeptide and reflecting the C-terminal se-
quence (present both in the precursor of b-Gal and in
S-Gal variant); and anti–P-Gal, raised to the 88-kD re-
combinant precursor of human b-Gal (and which rec-
ognizes both variants of human b-Gal) were produced
and characterized as described elsewhere (Hinek et al.
1993; Zhang et al. 1994; Okamura-Oho et al. 1996).
The b-Gal substrate, 4-methylumbelliferyl-b-D-galacto-
pyranoside, was from Koch-Light Laboratories, Ltd. All
other chemicals, proteinase inhibitors, enzyme sub-
strates, SDS-PAGE reagents, fluorescein (FITC)- and
horseradish peroxidase (HRP)–conjugated secondary
antibodies were purchased from Sigma. The enhanced
chemiluminescence (ECL) western-blotting detection kit
was from Amersham Canada Ltd. Radioactive [14C]-ser-
ine and [3H]-valine were supplied by New England Nu-
clear. The protein-assay kit was from BioRad.
Fibroblasts and Tissue Preparation
Human skin fibroblasts were propagated in the cell
repository of The Hospital for Sick Children in Toronto
(HSC). Fibroblasts were derived from forearm-skin bi-
opsies of three normal children—patients 3858 (age 4
mo), 4212 (age 7 mo), and 4184 (age 36 mo)—and from
two patients clinically diagnosed with the infantile phe-
notype of GM1-gangliosidosis that bear missense mu-
tations of the b-Gal gene (R148S/D332N in case 4992
and R148S/R482H in case 8981) and nonsense muta-
tions R351X (case 4032) and R475X (case 8982). Both
patients with missense mutations (patient 4992, a 12-
mo-old male; and patient 8981, a 34-mo-old female)
demonstrated a relatively mild clinical phenotype with
hepatosplenomegaly but no visible skeletal deformations
or cardiac involvement. The residual values of their se-
rum and leukocyte b-Gal activity (4% and 6%of control
values, respectively) were consistent with a diagnosis of
GM1-gangliosidosis. In contrast, both patients with
nonsense mutations of b-Gal gene (patient 4032, an 18-
mo-old female; and patient 8982, a 3-mo-old male), in
addition to having hepatosplenomegaly and skeletal dys-
plasia, initially were diagnosed with cardiomegaly and
congestive heart failure. Cardiac ultrasound examina-
tion demonstrated left-ventricular and septal hypertro-
phy and diminished contractility in both cases. Their
values of serum and leukocyte b-Gal activity were !2%
of control values.
In addition, fibroblasts from two patients with an
adult form of GM1-gangliosidosis (patients 3633 and
3749) and with b-Gal deficiency reaching, in both cases,
12% of normal value (mutations unknown) also were
tested. These patients demonstrated characteristic extra-
pyramidal neurological symptoms but no skeletal de-
formities or cardiac involvement.
Morquio B disease fibroblasts were from three newly
diagnosed patients with HSC that bear recently de-
scribed b-Gal gene mutations localized to the coding
region common to lysosomal enzyme and S-Gal/EBP
protein (Skomorowski et al. 1999) (patient 10213, a
G438E homozygote; patient 11983, an N484K/T500A
heterozygote; and patient 11984, a N484K/T500A het-
erozygote) and from one case, described elsewhere (Osh-
ima et al. 1991), who was a W273L/R482H heterozy-
gote obtained from the National Institute of General
Medical Sciences cell repository (patient 4080). All fi-
broblasts originally isolated by collagenase digestion of
the skin-biopsy samples were routinely passaged by tryp-
sinization and were maintained in alpha-minimum es-
sential medium (a-MEM) supplemented with 20 mM
HEPES, 1% antibiotics/antimycotics, 10% fetal bovine
serum, and 1% L-glutamate. Expression of EBP and of
lysyl oxidase, as well as deposition of extracellular elas-
tin, collagen type I, laminin, fibronectin, and fibrillin,
were compared by immunohistochemistry at passages
2–5.
In a separate series of experiments, we tested whether
delivery of exogenous S-Gal/EBP would restore normal
deposition of elastic fibers byMorquio B disease (patient
4080) and GM1-gangliosidosis fibroblasts homozygous
for the R351X mutation (patient 4032), deficient in S-
Gal. These fibroblasts ( cells) were mixed with61# 10
Chinese hamster ovary (CHO) cells perma-52# 10
nently transfected with an S-Gal cDNA clone and co-
cultured in normal medium. The parallel cocultures of
fibroblasts from patients 4080 and 4032, mixed with a
comparable number of nontransfected CHO cells, were
used for comparison. Both types of cocultures were ter-
minated after 3 and 10 d, and production of elastic fibers
was assessed by immunohistochemistry and by insolu-
ble-elastin assay, as described below.
Stable transfection of CHO cells with S-Gal cDNA
was performed as described elsewhere (Zhang et al.
1994). In brief, the S-Gal cDNA was subcloned into the
mammalian expression vector pRc/RSV (Invitrogen), at
theHindIII site. CHO cells (American Type Culture Col-
lection) were exposed to the DNA-Lipofectin complex
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for 5 h, in serum-free a-MEMmedium, after which time
the cells were incubated in a-MEM medium containing
10% fetal calf serum, for 48–72 h. Transfected cellswere
selected with geneticin (G418), at a concentration of 400
mg/ml, in the above medium. After 14 d, the clones
resistant to geneticin were separately isolated. To assess
their ability to produce S-Gal, the cells were lysed in 1%
octyl-b-D-glucoside (OBG) and were characterized by
western blots. Clone 42 showed the strongest signal of
S-Gal and was selected for use. By correlating PCR and
RT-PCR primer products reflecting the frameshifted
exon 5 (Privitera et al. 1998) and anti–S-Gal antibody
reactivity performed as described elsewhere (Hinek et al.
1993), we showed that this DNA fragment was synthe-
sized only in the S-Gal–transfected clones, and not in
the nontransfected CHO cells. To test whether delivery
of exogenous enzymatically active b-Gal would also re-
verse faulty elastogenesis, GM1-gangliosidosis (patient
4032) and Morquio B disease fibroblasts (patient 4080)
were plated on glass cover slips and were placed (face
up) on the top of subconfluent cultures of CHO cells
permanently transfected with wild-type b-Gal cDNA
and secreting the active enzyme into the conditioned
medium (Zhang et al. 1994). Both types of cocultures
were terminated after 10 d. Production of elastic fibers,
as well as expression of S-Gal, were assessed by im-
munohistochemistry and by insoluble-elastin assay, as
described below. The enzymatically active b-Gal pre-
cursor taken up by cultured fibroblasts was histochem-
ically visualized with X-Gal substrate, as described else-
where (Singh and Knox 1984).
Immunostaining
Subconfluent 2-d-old cultures of normal, GM1-gan-
gliosidosis, and Morquio B disease fibroblasts, as well
as 10-d-old dense cultures of these cells, which produce
abundant extracellular matrix, were used. The 2-d-old
cultures were fixed in cold 100% methanol at 20C
for 30 min and were incubated for 1 h, with either anti-
S-Gal antibody (20 mg/ml), an antibody that recognizes
the elastin-binding domain of the S-Gal (Hinek et al.
1993), or monoclonal antibody (BCZ) (25 mg/ml), an
antibody that recognizes a different epitope on this EBP
(Mecham et al. 1989).
The 10-d-old confluent cultures of the normal, GM1-
gangliosidosis, and Morquio B disease fibroblasts were
fixed for 30 min in cold 100% methanol, and then par-
allel cultures were immunostained with polyclonal an-
tibody to tropoelastin (20 mg/ml), monoclonal antibody
to fibronectin (1 mg/ml), monoclonal antibody to laminin
(1 mg/ml), or polyclonal antibody to collagen type I (1
mg/ml), as described elsewhere (Hinek andWilson 2000).
Cultures scheduled for immunohistochemical assess-
ment of microfibrils were fixed in 0.5% paraformalde-
hyde at room temperature for 15 min, were blocked in
PBS containing 0.1 M ammonium chloride, and then
were washed in PBS and were treated with polyclonal
antibody to fibrillin-1 (20 mg/ml). In addition to this,
cultures of all tested fibroblasts also were probed with
antibody recognizing lysyl oxidase (1 mg/ml), an enzyme
responsible for cross-linking of the secreted tropoelastin.
All cultures were incubated with the appropriate FITC-
conjugated secondary antibodies (GAR-FITC or GAM-
FITC) for an additional hour, and nuclei were coun-
terstained with propidium iodide; as a control for all
immunostaining described, the preimmune rabbit IgG or
normal mouse ascitic fluid, respectively, was substituted
for the primary antibodies. Additional controls included
secondary antibody alone.Morphometric analysis of 10-
d-old cultures immunostained with antibodies recogniz-
ing extracellular matrix components was performed by
an Olympus AH-3 microscope attached to a CCD cam-
era (Optronics) and a computer-generated video-analysis
system (Image-Pro Plus software; Media Cybernetics).
In each analyzed group, 50 low-power fields (20#)
from three separate cultures (derived from different pa-
tients) were analyzed, and the area occupied by the par-
ticular immunodetectable component was quantified.
The abundance of each immunodetectable component
was then expressed as a percentage of the entire analyzed
field.
Assay of b-Galactosidase Proteins and Enzymatic
Activity
Confluent dishes of fibroblasts (∼5 # 106 cells/dish)
maintained in a-MEM containing heat-inactivated 10%
fetal calf serum, were washed three times in PBS (10
mM phosphate, 0.15 M NaCl [pH 7.4]), and the cells
were harvested by scraping with a rubber policeman.
The cells were then briefly centrifuged at 100 g, were
resuspended in 0.1 M Tris-HCl, pH 7.6, containing 2
mM phenylmethylsulfonyl fluoride (PMSF) protease in-
hibitor, and were lysed by three cycles of freezing and
thawing. To detect all b-Gal–related proteins, 20-ml ali-
quots of the cell extracts were mixed with an equal vol-
ume of carbon tetrachloride. After the insoluble cell rem-
nants were removed by centrifugation, the extract was
subjected to SDS-PAGE, followed by immunoblotting
with the polyclonal antibody raised to the b-Gal pre-
cursor (anti–P-Gal) that recognizes all forms of b-Gal
and S-Gal and their degradation products. The enzy-
matic activity of b-Gal was determined in supernatants
using 4-methylumbelliferyl-b-D-galactopyranoside, as
described elsewhere (D’Agrosa et al. 1992), and results
were normalized for total protein content (assessed by
a BioRad kit).
Isolation of EBP
To compare patterns of EBP expression by the normal,
GM1-gangliosidosis, andMorquio B fibroblasts, we car-
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ried out metabolic labeling followed by elastin-affinity
chromatography. Fibroblasts were initially plated 1#
cells/dish. The quadruplicate cultures were main-610
tained in serum-free Medium 199 for 6 h and then were
exposed to 15 mCi [14C]-serine/ml, in serine-freemedium,
for 3 h. The cultures were then rinsed well, and the cell
layers and the media were processed separately. To iso-
late the EBP from the cell layers, elastin-affinity chro-
matography was used. Fibroblasts were scraped from
each culture dish, suspended in 1 ml of 0.1 M bicar-
bonate buffer, pH 8, and were extracted, for 1 h at 4C,
with 0.1 M lactose, 0.1 M dithiothreitol (DTT), and
0.25% OBG, in the presence of proteinase inhibitors in
the following final concentrations: 2 mM benzamidine,
2 mM epsylon amino capronic acid, 2 mM PMSF, 1 mM
EDTA, and 1 mg trasylol/ml. The EBP present in extracts
of each culture was then purified by insoluble-elas-
tin–affinity chromatography using minicolumns each
made of 1 mg of insoluble elastin slurries, as described
elsewhere (Hinek et al. 1993; Privitera et al. 1998). The
elastin-bound proteins were released from the insoluble
slurries by boiling in 62.5 mM Tris-HCl buffer, pH
6.8, containing 2% SDS, 10% glycerol, 5% mercapto-
ethanol, and 0.001% bromophenol blue with DTT and
were resolved by 7.5%–12% SDS-PAGE, followed by
autoradiography. The identity of the 67-kD EBP was
additionally confirmed by immunoblotting with anti-S-
Gal, anti-C-Gal, anti-P-Gal, and anti-EBP (BCZ) anti-
bodies (all in a concentration of 0.2 mg/ml), followed by
the appropriate HRP-conjugated secondary antibodies
diluted 1:5,000, and signals were developed with the
ECL detection system. The b-Gal proteins (precursor,
active enzyme, and S-Gal) also were isolated from the
cell lysates and were concentrated by affinity chroma-
tography on p-aminophenyl-thiogalactose-Sepharose
(Hinek et al. 1993).
Tropoelastin and Insoluble Elastin Assays
Normal, GM1-gangliosidosis, and Morquio B fibro-
blasts were grown to confluency in 10-cm cell-culture
dishes, in quadruplicate. To each dish was added 20 mCi
of [3H]-valine, along with fresh media. Cultures were
then incubated for 72 h, and soluble and insoluble elastin
were assessed separately in each culture. First, media
were collected and immunoprecipitated with a polyclo-
nal antibody to tropoelastin; then the soluble proteins
present in the intracellular compartments were extracted
for 6 h, with 0.1 M acetic acid, and the intracellular
tropoelastin was immunoprecipitated from each extract,
as described elsewhere (Hinek and Rabinovitch 1994),
and then was quantitatively assessed after scintillation
counting. The remaining cultures, containing cell rem-
nants and deposited insoluble extracellular matrix, were
then scraped in 0.1 N NaOH, were sedimented by cen-
trifugation, and were boiled in 0.5 ml of 0.1 N NaOH
for 45 min, to solubilize all matrix components except
elastin. The resulting pellets, containing the insoluble
elastin, then were solubilized by being boiled in 200 ml
of 5.7 N HCl for 1 h, and the aliquots were mixed with
scintillation fluid and were counted (Hinek and Rabino-
vitch 1993, 1994).
Analysis of Data
In all biochemical studies, means and SDs were cal-
culated, and statistical analyses were carried out by
ANOVA.
Results
Lack of S-Gal in Morquio B Disease and GM1-
Gangliosidosis Cells Bearing Nonsense b-Gal
Mutations
Assays utilizing the enzyme-specific substrates indi-
cated that all tested fibroblasts derived from patients
with either Morquio B disease and or GM1-gangliosi-
dosis displayed levels of hexaminidase similar to those
in normal fibroblasts (16,735–22,248 nM/h/mg pro-
tein), but they were characterized by only residual levels
of enzymatic activity of acid b-Gal (3–47 nM/h/mg pro-
tein), compared with normal fibroblasts (2,900–3,730
nM/h/mg protein). Western-blot analysis of cell lysates
with anti–P-Gal antibody indicated that Morquio B and
GM1-gangliosidosis fibroblasts demonstrated variable
amounts of 88-kD b-Gal precursor but very little or none
of the mature, 64-kD form of the enzyme. Interestingly,
only normal fibroblasts and GM1-gangliosidosis fibro-
blasts bearing missense mutations of b-Gal displayed the
presence of the 67-kD protein immunoreactive with
anti–P-Gal antibody (fig. 1). This was consistent with
results of another experiment, aimed at isolation of the
EBPs metabolically labeled with radioactive serine. SDS-
PAGE followed by autoradiography showed that the
whole-cell extracts of fibroblasts derived from patients
with infantile GM1-gangliosidosis that bear missense
mutations of b-Gal gene (patients 4992 and 8981) dem-
onstrated similar amounts of the labeled 67-kD protein
isolated by elastin-affinity columns, compared with nor-
mal fibroblasts (fig. 2). The 67-kD proteins released from
elastin-affinity columns strongly reacted with anti–S-Gal
antibody on western blots and also were recognized by
anti–C-Gal, anti–P-Gal, and anti-EBP antibodies. The
67-kD species was the only protein retained on elastin-
affinity columns; in contrast, fibroblasts derived from an
infantile form of GM1-gangliosidosis that bear nonsense
Arg351X and R475X mutations of the b-Gal gene (in
patients 4032 and 8982, respectively), as well as fibro-
blasts derived from all four tested cases of Morquio B
disease, did not display labeled 67-kD protein that could
bind to elastin-affinity column and that could react with
anti–S-Gal, anti–P-Gal, anti–C-Gal, or anti-EBP anti-
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Figure 1 Representative western blotting with anti–P-Gal an-
tibody detecting b–Gal–related species (88-kD precursor, 67-kD S-Gal,
and 64-kD mature enzyme—and their degradation products) in lysates
of human skin fibroblasts. Morquio B fibroblasts (11984) and GM1-
gangliosidosis fibroblasts (4992 and 4032) demonstrate variable
amounts of 88-kD b-Gal precursor but little or none of the mature
64-kD enzyme. In contrast to normal (4212) and GM1-gangliosidosis
fibroblasts bearing missense (m.m.) mutations of b-Gal (4992), which
display the 67-kD immunoreactive protein, neither GM1-gangliosi-
dosis fibroblasts (4032) bearing the nonsense mutation (n.m.) nor cells
from Morquio B patient (11984) show any trace of the 67-kD species.
Figure 2 SDS-PAGE of whole-cell extracts, followed by auto-
radiography. The amount of metabolically labeled, newly produced
67-kD protein isolated by elastin-affinity columns is similar in fibro-
blasts derived from a patient with infantile GM1-gangliosidosis that
bear missense mutations of the b-Gal gene (GM1 m.m. lanes 4992
and 8981) and in fibroblasts obtained from normal individuals (NF
lanes 3858 and 4212). The parallel western blots demonstrate that
newly synthesized 67-kD protein that binds to the elastin-affinity col-
umn and reacts with anti–S-Gal antibody is also recognized by anti–C-
Gal, anti–P-Gal, and BCZ antibodies. In contrast, GM1-gangliosidosis
fibroblasts bearing nonsense mutations of the b-Gal gene (GM1 n.m.
lanes 4032 and 8982), as well as Morquio B fibroblasts (MB lanes
11983, 11984, 10213, and 4080) do not display radiolabeled and
immunoreactive S-Gal/EBP.
bodies. Interestingly, fibroblasts from patients with an
adult form of GM1-gangliosidosis that did not display
connective-tissue abnormalities (cases 3749 and 3633)
demonstrated similar amounts of the labeled 67-kD pro-
tein isolated by elastin-affinity columns, when compared
with fibroblasts obtained from normal individuals (data
not shown).
Fibroblasts from Morquio B Disease and GM1-Gan-
gliosidosis That Do Not Express S-Gal but Show
Impaired Secretion of Tropoelastin and Do Not
Assemble Elastic Fibers
Immunocytochemistry with anti–S-Gal antibody dem-
onstrated clear localization of the EBP on the surface of
nonpermeabilized cultured fibroblasts obtained from
normal controls and from patients with GM1-gangliosi-
dosis with missense b-Gal mutations (fig. 3A and B). In
contrast, neither fibroblasts from a patients with GM1-
gangliosidosis that bear a nonsense b-Gal mutation (fig.
3C) nor Morquio B fibroblasts (fig. 3D) displayed an S-
Gal immunodetectable protein. Cultures of fibroblasts
from patients with an adult form of GM1-gangliosidosis
showed normal production of S-Gal (data not shown).
Immunostaining with a BCZ antibody recognizing a dif-
ferent epitope on the S-Gal/EBP showed similar patterns
of localization, on all tested fibroblasts.
The lack of S-Gal expression correlated with impaired
elastic-fiber production. Comparison of 10-d-old fibro-
blast cultures immunostained with an anti-tropoelastin
antibody revealed that, in contrast to normal fibroblasts
(fig. 3E) and GM1-fibroblasts with missense mutations
(fig. 3F) that produced a dense network of elastic fibers,
the fibroblasts from the patient withGM1-gangliosidosis
that bear the nonsense mutation (fig. 3G) and from the
patient with Morquio B disease (fig. 3H) did not dem-
onstrate immunodetectable extracellular elastin. This
was in contrast to cultures of fibroblasts from patients
with an adult form of GM1-gangliosidosis (showing nor-
mal expression of S-Gal), which produced as many elas-
tic fibers as were produced by fibroblasts obtained from
normal individuals (data not shown). Morphometric
analysis of 10-d-old cultures immunostained with ma-
trix-specific antibodies indicated that the S-Gal–deficient
fibroblasts were selectively afflicted with the inability to
deposit elastic fibers, but they demonstrated normally
assembled microfibrils (detected by an antibody to fi-
brillin-1) and normal amounts of immunodetectable col-
Figure 3 A–D, Representative high-power photomicrographs depicting immunostaining with anti–S-Gal antibody, which recognizes EBP.
Normal fibroblasts (A) and GM1-gangliosidosis fibroblasts bearing missense mutations of the b-Gal gene (B) demonstrate strong cell-surface
expression of this protein, whereas GM1-gangliosidosis fibroblasts bearing nonsense mutations of the b-Gal gene (C) and Morquio B fibroblasts
(D) show no immunodetectable S-Gal/EBP. E–H, Representative photomicrographs of 10-d-old cultures immunostained with anti-tropoelastin
antibody, indicating that normal fibroblasts (E) and fibroblasts bearing missense mutations of the b-Gal gene (F) produce long, branching elastic
fibers, whereas fibroblasts from patients with GM1-gangliosidosis bear nonsense mutations of the b-Gal gene (G), and Morquio B fibroblasts
(H) do not deposit any extracellular elastin.
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Figure 4 Morphometric analysis of extracellular-matrix com-
ponents immunostained with specific antibodies in 10-d-old cultures
of normal, GM1-gangliosidosis, and Morquio B fibroblasts. Fibro-
blasts from GM1-gangliosidosis fibroblasts bearing nonsense muta-
tions of the b-Gal gene (n.m.), as well as Morquio B fibroblasts deposit
only negligible amounts of immunodetectable extracellular elastin. The
amounts of fibrillin 1, fibronectin, collagen type I, and laminin pro-
duced by those fibroblasts do not differ from what is produced by
either normal fibroblasts or GM1-gangliosidosis fibroblasts bearing
missense mutations (m.m.) of the b-Gal gene. In each group, 50 low-
power (20#) fields from three separate cultures (per independent pa-
tient) were analyzed, and the area occupied by the particular immu-
nodetectable component was quantified. The abundance of each
component was then expressed as a percentage (mean  SD) of the
entire analyzed field, and results from cultures of GM1-gangliosidosis
fibroblasts and Morquio B fibroblasts were statistically comparedwith
those in cultures of normal skin fibroblasts. An asterisk (*) denotes
.P ! .001
lagen type I, laminin, and fibronectin (fig. 4). It should
also be stressed that all tested fibroblasts displayed an
equally good immunodetectable expression of lysyl oxi-
dase, an enzyme responsible for tropoelastin cross-link-
ing (data not shown).
Impaired deposition of insoluble elastin by the S-
Gal–deficient fibroblasts visualized by immunocyto-
chemistry was additionally confirmed by metabolic tests.
Quantitative assessment of [3H]-valine incorporation
into immunoprecipitable soluble tropoelastin extracted
jointly from the cell layers and from the conditioned
media showed that all tested Morquio B disease and
GM1-gangliosidosis fibroblasts synthesized amounts of
tropoelastin comparable to those seen in normal fibro-
blasts (fig. 5A). Selective immunoprecipitation of met-
abolically labeled tropoelastin from the cell layers
showed that, in contrast to cultures of normal fibroblasts
and GM1-gangliosidosis cells that bear missense muta-
tions of b-Gal gene, the cell-layer fractions of fibroblasts
from S-Gal–deficient patients retained the majority of
the radioactive tropoelastin intracellularly. Cultures of
these cells consistently incorporated very little [3H]-val-
ine into NaOH-insoluble elastin. These results indicate
that the deficiency in S-Gal did not affect normal tro-
poelastin synthesis but that it did correlate with impaired
tropoelastin secretion and extracellular assembly into in-
soluble elastin, a major component of elastic fibers.
Uptake of Exogenous S-Gal—but Not Enzymatically
Active b-Galactosidase—by S-Gal–Deficient Morquio B
and GM1-Gangliosidosis Fibroblasts: Improvement in
Assembly of Elastic Fibers
Both immunocytochemistry andmetabolic labeling in-
dicated that S-Gal–deficient fibroblasts (patients 4032
and 4080) restored deposition of elastic fibers when their
physical contact was maintained with cocultured CHO
cells permanently transfected with the S-Gal cDNA but
that this was not the case with untransfected CHO cells
(figs. 5B and 6A–D). Such restoration of elastin depo-
sition by these fibroblasts correlated with the appearance
of their immunostaining with anti–S-Gal antibody (fig.
6). S-Gal–deficient fibroblasts did not display any im-
munostaining with anti–S-Gal antibody when they were
cocultured with nontransfected CHO cells. These data
indicate that the cell-surface–targeted S-Gal protein pro-
duced by CHO cells was translocated to the adjacent
fibroblasts, on the close physical contact between both
cell types. Interestingly, delivery of active b-Gal, secreted
from CHO cells expressing the enzyme and also taken
up by tested fibroblasts, did not enhance their ability to
deposit insoluble elastin (fig. 6E–H).
Discussion
Elastin is often thought to be produced during the late
stages of fetal life and during the perinatal period (Cleary
et al. 1967; Mecham and Hauser 1991; Rosenbloom et
al. 1993; Pasquali-Ronchetti and Baccarani-Contri
1997). In situ hybridization has revealed that tropoe-
lastin mRNA is expressed in the early stages of chick-
embryo development (Selmin et al. 1991; Holzenberger
et al. 1993). Studies by Hurle et al. (1994) also dem-
onstrated the presence of elastic fibers during early mor-
phogenesis of the limb skeleton and suggested that the
elastic-fiber scaffold plays an important role in coordi-
nating the size, shape, and spatial location of the car-
tilaginous skeletal elements within the limb buds. Hurle
et al. also observed precise patterns of elastic-fiber ar-
rangement present in the outflow tract and atrioven-
tricular-cushion tissue of the heart, the early developing
lung, the notochord, and the somites. These observations
pointed to previously unsuspected functions for elastic
matrices during embryonic development and substanti-
ated our hypothesis—that is, that impaired elastogenesis
in the developing skeleton, heart, or connective tissue
may be a common denominator in the pathophysiology
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Figure 5 A, upper graph, Quantitative analysis of [3H]-val-
ine–labeled immunoprecipitable tropoelastin, indicating that all
tested fibroblasts (i.e., normal, GM1-gangliosidosis, and Morquio
B) synthesize comparable amounts of total metabolically labeled
tropoelastin. A, middle graph, Fibroblasts from normal individuals
(3858, 4184, and 4212), infantile GM1-gangliosidosis fibroblasts
with missense mutations of the b-Gal gene (4992 and 8981), and
fibroblasts from the adult form of GM1–gangliosidosis (3633 and
3749), which retained very little newly produced tropoelastin in-
tracellularly. In contrast, fibroblasts from patients with infantile
GM1-gangliosidosis that bear nonsense mutations of the b-Gal
gene (4032 and 8982), as well as Morquio B fibroblasts (4080,
10213, 11983, and 11984) retain the majority of their metaboli-
cally labeled tropoelastin intracellularly. A, lower graph, S-Gal–
deficient fibroblasts, all of which incorporate very little [3H]-valine
into extracellular insoluble elastin. B, Metabolic labeling of cul-
tured fibroblasts with [3H]-valine, followed by quantitative anal-
ysis of radiolabeled NaOH-insoluble residues, demonstrating that
S-Gal–deficient fibroblasts (4032 and 4080) show normal depo-
sition of insoluble elastin when maintained in the mixed culture
with CHO cells permanently transfected with the S-Gal cDNA but
do not do so with untransfected CHO cells. Coculture of neither
GM1-gangliosidosis fibroblasts bearing nonsense mutations of the
b-Gal gene (4032) nor Morquio B fibroblasts with b-Gal cDNA-
transfected CHO cells secreting enzymatically active precursor
(taken up by these fibroblasts deficient in both variants of b-Gal)
improved deposition of insoluble elastin.
of different inherited diseases with dysmorphic pheno-
types. Moreover, inherited diseases that manifest skeletal
deformities are often characterized by such common fea-
tures as loose skin, ligamentous laxity, hernias, cardio-
megaly, and cardiac valvular deformities, which further
suggest a common disorder involving impaired elastic-
fiber production.
Among all inherited diseases that affect the structure,
distribution, and abundance of elastic fibers, only su-
pravalvular aortic stenosis, Williams syndrome, and cu-
tis laxa have been directly linked to primary alterations
in the elastin gene (Curran et al. 1993; Ewart et al. 1993,
1994; Tassabehji et al. 1997). Other genetic diseases
that severely affect elastic-fiber integrity (e.g., Marfan
syndrome, pseudoxanthoma elasticum, andMenkes dis-
ease) have been linked either to primary defects in mi-
crofibrillar proteins or to errors in copper metabolism
and lysyl oxidase (Sandberg et al. 1981; Lee 1991; Me-
cham and Hauser 1991; Rosenbloom et al. 1993; Chris-
tiano and Uitto 1994; Pasquali-Ronchetti and Baccar-
ani-Contri 1997; Vrhovski and Weiss 1998; Debell and
Tamburro 1999). Since the 67-kD EBP that plays a cru-
cial role in elastogenesis has been definitively charac-
terized as an inactive spliced variant of b-Gal, we in-
vestigated the possibility that either the functional
inactivation of S-Gal/EBP or faulty primary expression
of the b-Gal gene could result in impaired elastic-fiber
assembly. This is in keeping with our recent studies dem-
onstrating that excessive tissue accumulation of der-
matan sulfate in Hurler disease, which causes constant
shedding of the EBP, leads to faulty elastogenesis (Hinek
and Wilson 2000). Disruption of elastic-fiber produc-
tion was demonstrated also in cultures of normal fibro-
blasts, chondroblasts, and arterial smooth muscle ex-
perimentally depleted of the EBP, after either treatment
with exogenous lactose, galactose, chondroitin sulfate,
and dermatan sulfate or blocking of this tropoelastin
chaperone by anti–S-Gal antibody (Hinek et al. 1988,
1991, 1992, 1993).
In the present study, we have used (a) skin fibroblasts
from four patients with Morquio B disease that bear
b-Gal gene mutations (G438E, N484K/T500A, and
W273L/R482H) localized to the coding region common
to lysosomal enzyme and S-Gal/EBP protein and (b)
fibroblasts from two patients with GM1-gangliosidosis
that bear nonsense mutations (R351X and R475X),
which also destabilize both b-Gal and S-Gal mRNAs
and which, consequently, may lead to deficiency in both
protein variants. We hypothesized that these cells would
not produce S-Gal and that such primary deficiency of
this tropoelastin chaperone would be sufficient for im-
paired elastogenesis. We also tested expression of S-Gal/
EBP and elastic-fiber formation in cultures of (a) skin
fibroblasts obtained from two patients with GM1-gan-
gliosidosis that bear a missense R148S mutation local-
Figure 6 A–D, Representative micrographs depicting 10-d-old GM1-gangliosidosis fibroblasts bearing nonsense mutations of the b-Gal
gene (4032) maintained in mixed culture, with CHO cells permanently transfected with the S-Gal cDNA clone (B andD) or with nontransfected
CHO cells (A andC). Immunostaining with anti–S-Gal antibody and FITC-conjugated secondary antibody indicates that cultured 4032fibroblasts
cocultured with untransfected CHO cells do not display any S-Gal antigen (A). In contrast, the same fibroblasts cocultured with CHO cells
permanently transfected with the S-Gal cDNA demonstrate the presence of green fluorescence–marked S-Gal protein (B). Immunostaining of
the parallel cultures with anti-elastin antibody and FITC-conjugated secondary antibody indicates that 4032 fibroblasts restored deposition of
elastic fibers when cocultured with S-Gal cDNA–transfected CHO cells (D) but not with untransfected controls (C). Note that CHO cells that
were loosely siting on top of the fibroblast layers for the duration of the experiment were washed out just before fixation. E–H, Histochemical
detection of b-Gal activity, marked by the dark-blue precipitate of X-Gal substrate, indicating that GM1-gangliosidosis fibroblasts bearing
nonsense mutations of the b-Gal gene (4032) uptake enzymatically active b-Gal precursor secreted from b-Gal cDNA–transfected CHO cells
(F) but not from untransfected CHO cells (E). Immunostaining of parallel cultures with anti-elastin antibody indicate that 4032 fibroblasts
cocultured with either untransfected CHO cells (G) or b-Gal cDNA–transfected CHO cells (H) were incapable of normal deposition of elastic
fibers.
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ized to the exon 4 of the b-Gal gene that is spliced out
of S-Gal and that might not affect synthesis of S-Gal/
EBP protein and (b) fibroblasts from two patients with
an adult form of GM1-gangliosidosis that did not dis-
play any connective-tissue problems.
Both immunocytochemistry (fig. 3C and D) and met-
abolic pulse labeling of cultured fibroblasts (fig. 5)
clearly demonstrated that tested Morquio B disease fi-
broblasts and fibroblasts from patients with GM1-gan-
gliosidosis that bear a nonsense mutations of the b-Gal
gene did not synthesize S-Gal at all, attesting to their
primary deficiency of EBP. Further immunochemical
and biochemical studies indicated a strong correlation
between deficiency in S-Gal and a selective impairment
of elastic-fiber production. We found that neither GM1-
gangliosidosis cells bearing nonsense mutations of the
b-Gal gene nor Morquio B cells bearing mutations re-
sulting in deficiency in both mature b-Gal and S-Gal
produced elastic fibers. This was in contrast to GM1-
gangliosidosis fibroblasts bearing missense mutations in
the b-Gal gene, which were deficient only in the lyso-
somal variant of b-Gal but synthesized normal amounts
of S-Gal and demonstrated normal deposition of insol-
uble elastin. Impaired production of elastic fibers by S-
Gal–deficient fibroblasts appears to be very distinctive,
since deposition of fibronectin, laminin, and collagen
type I was not affected. It should also be mentioned that
all tested cells derived from the syndromes discussed
above synthesized amounts of the [3H]-valine–labeled
soluble tropoelastin that were similar to the levels seen
in cells taken from healthy individuals, which produced
an abundant network of microfibrils (marked by normal
distribution of fibrillin-1), which is required for extra-
cellular assembly of secreted tropoelastin into elastic
fibers. Moreover, immunocytochemistry with an anti-
body to lysyl oxidase also tested for normal expression
of this enzyme responsible for extracellular cross-linking
of newly deposited tropoelastin monomers into an in-
soluble elastin polymer.
These data excluded the possibility of a primary de-
ficiency in any of the major components that normally
build elastic fibers. Our results clearly indicate, however,
that newly synthesized tropoelastin could not be prop-
erly secreted from the S-Gal–deficient cells and, con-
sequently, assembled into extracellular elastic fibers.
The exquisite importance that the S-Gal/EBP has for
the processes of normal elastogenesis was additionally
confirmed by results indicating that S-Gal–deficient fi-
broblasts (patients 4032 and 4080) were capable of nor-
mal deposition of the elastic fibers when coculturedwith
CHO cells permanently transfected with S-Gal cDNA
clone. Restoration of elastin deposition by those fibro-
blasts correlated with the immunodetectable presence
of S-Gal protein at their cell surface and indicates that
the S-Gal molecules produced by CHO cells were trans-
located to the adjacent fibroblasts. Since the S-Gal/EBP
has been identified as a recyclable and reusable tropo-
elastin chaperone (Hinek et al. 1995), it is possible that
this protein, when taken up to the endosomal com-
partment of fibroblasts, resumes its basic function, binds
tropoelastin, and facilitates its secretion and assembly.
That there is specific benefit of such S-Gal delivery is
reinforced by the fact that intracellular uptake of en-
zymatically active wild-type b-Gal by Morquio B and
GM1-gangliosidosis fibroblasts did not improve their
deposition of insoluble elastin.
Since the presence of elastic fibers in the limb buds
and their primitive perichondrial tissue has been sug-
gested as a crucial factor responsible for maintaining
the proper shape of embryonal skeleton (Hurle et al.
1994), our results indicate that cellular deficiency, in S-
Gal, leading to disruption of elastic-fiber formationmay
be relevant to the skeletal deformations observed in
Morquio B disease and in selected cases of GM1-gan-
gliosidosis. However, further studies, using fetal autopsy
tissues, would be required in order to confirm this
possibility.
Until recently, no one has been able to correlate the
presence of cardiac abnormalities with specific genetic
lesions of the b-Gal gene. A recent report by Morrone
et al. (2000) has described six newly diagnosed patients
with GM1-gangliosidosis with cardiac involvement
who were homozygous for either of the following mu-
tations: R59H, Y591C, Y591N, or IVS142ArG, oc-
curring in the coding region common to lysosomal en-
zyme and S-Gal/EBP protein. The authors of that report
therefore have concluded that the cardiac involvement
in these patients is likely caused by an alteration at the
homozygous state of the expression of EBP. This report
strongly reinforces a pathophysiological link between
S-Gal deficiency and cardiomyopathy, which also has
been observed in other genetic diseases characterized by
impaired elastogenesis (Haust 1987; Dangel 1998; Hi-
nek andWilson 2000). The results reported byMorrone
et al. (2000) also are consistent with our present data
indicating that fibroblasts from two cases of infantile
GM1-gangliosidosis that demonstrated skeletal and car-
diac abnormalities (fibroblasts bearing a nonsense mu-
tations of b-Gal gene) were deficient in S-Gal protein
and did not assemble elastic fibers in vitro. We therefore
suggest that S-Gal deficiency resulting in impaired elas-
togenesis might contribute to lack of properly assembled
elastin fibers in the heart, thereby resulting in an ab-
errant connective-tissue framework allowing for hyper-
trophic growth of cardiomyocytes.
It has to be mentioned that donors of the S-Gal–
deficient fibroblasts (i.e., patients with either Morquio
B disease or GM1-gangliosidosis) did not demonstrate
any disseminated elastopathy in arteries, lung, or skin.
The preservation of elastic fibers in these tissues seems
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to be due to unknown compensatory mechanisms,
which may derive either from the higher rate of tro-
poelastin biosynthesis and/or from activation of S-
Gal–independent routes of tropoelastin secretion and
assembly. Elsewhere, it has been shown that tropoelas-
tin can also bind to other intracellular chaperones, such
as BIP and the peptidyl-prolyl cis-trans isomerase (Davis
et al. 1998).Moreover, Saunders andGrant (1985) dem-
onstrated that, in arterial SMC, 30%–40% of all syn-
thesized tropoelastin is not transported through the en-
dosomes and Golgi apparatus but can be rapidly
secreted through vesicles budding off the rough endo-
plastic reticulum in close proximity to the plasma
membrane. Thus, it is possible that, in certain cell types,
this mechanism can compensate for the S-Gal deficiency
and can assure production of normal-looking elastic
fibers. Nothing is known, however, about the durabil-
ity of such elastic fibers, which might be compromised
over time and cause clinical problems in longer-living
patients.
In summary, the present study has provided a novel
and natural model for exploration of the functional sig-
nificance of the nonlysosomal 67-kD alternative spliced
variant of b-Gal. Our data demonstrating that fibro-
blasts bearing natural b-Gal gene mutations that cause
deficiency in this protein do not assemble elastic fibers
ultimately confirm that the expression of S-Gal is a pre-
requisite for normal elastogenesis. We suggest that the
link between S-Gal deficiency and impaired elastogene-
sis can be relevant to the pathomechanism of charac-
teristic clinical features observed in patients with Mor-
quio B disease patients and in those patients with
infantile GM1-gangliosidosis with connective-tissue dis-
orders, skeletal deformation, and cardiomyopathy.
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